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ABSTRACT Accurate sizing of nanoparticles in biological media is important for drug delivery and biomedical imaging applications
since size directly influences the nanoparticle processing and nanotoxicity in vivo. Using fluorescence single particle tracking we
have succeeded for the first time in following the aggregation of drug delivery nanoparticles in real time in undiluted whole blood.
We demonstrate that, by using a suitable surface functionalization, nanoparticle aggregation in the blood circulation is prevented to
a large extent.
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There is a growing appreciation that a thorough un-derstanding of the fundamental interactions of nano-particles with biological materials is required to make
the transition from the laboratory to a successful and safe
product.1 In particular, the interaction with plasma and
blood components is currently of great interest since many
types of nanoparticles are intended for intravenous admin-
istration. Examples are functionalized nanoparticles for
biomedical imaging such as gold nanoparticles for X-ray
computer tomography or quantum dots for fluorescence
imaging.2 In the drug delivery field, nanomedicines are being
developed based on liposomal or polymeric carrier materials
to deliver therapeutic agents, such as anticancer drugs and
nucleic acids, to specific target tissues.3,4 While nanopar-
ticles can be accurately characterized in simple solvents at
the time of preparation, their efficacy will ultimately be
determined by their interaction with biopolymers and other
constituents of the blood circulation. For instance, recent
investigations have shown that typically a biopolymer co-
rona is formed around nanoparticles in plasma, depending
on their composition, size, and surface charge.5 Since this
corona alters their outer surface, it can influence the effective
nanoparticle behavior.6
Apart from their surface properties, a crucial parameter
is the effective size of nanoparticles in the blood circulation
because it directly influences their clearance and biodistribu-
tion,7-10 as well as their subsequent uptake and processing
by target cells.11,12 Furthermore, it is suggested that the
effective size of nanoparticles might be related to their
toxicity.13 Despite its importance, due to a lack of appropri-
ate techniques no studies have been reported so far where
the size and aggregation of nanoparticles has been studied
directly in undiluted biological fluids. While dynamic light
scattering (DLS) is arguably the most successful technique
to size nanoparticles in simple solvents, it is incompatible
with biological fluids since the particles of interest should
be dispersed in a solution free of other light scattering
components. Imaging techniques such as atomic force
microscopy and electron microscopy suffer from a poor
statistical power and require extensive preparation and
fixation steps that could result in morphological deformation
and misleading measurements. In a recent study, nanopar-
ticle tracking and analysis (NTA) was explored for sizing gold
nanoparticles in plasma. However, since the NTA technique
relies on the detection of scattered light, plasma had to be
diluted 106 times for the nanoparticles to be visible.14 In
another recent study, sizing of polystyrene model particles
in plasma was achieved with success using differential
centrifugal sedimentation although again the plasma was
diluted at least 50 times.6 Flow cytometry was recently
explored as an alternative method for sizing fluorescently
labeled nanomedicines in serum.15 However, it was recog-
nized that interpretation of absolute size values should be
done with caution as the data quantification depends on the
shape, surface structure, and refractive index of the particles.
Here we report on the first study on the effective size of
nanoparticles in undiluted biological fluids like plasma and
whole blood by using fluorescence single particle tracking
(fSPT). fSPT is a microscopy technique that allows one to
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image the movement of individual fluorescently labeled
nanoparticles with nanometer precision and has mostly
been used for studying the mobility of biomolecules and
nanomedicines in living cells.16-19 While it has been previ-
ously realized that fSPT can be used for measuring the size
of hard sphere colloids in a simple dispersion,20 here we
demonstrate for the first time that this technique, when
combined with maximum entropy analysis, allows one to
measure in real-time accurate and precise size distributions
of nanoparticles dispersed in undiluted biological fluids. After
a detailed validation, we apply fSPT to study the time-
dependent aggregation of liposomes with different surface
functionalizations in whole blood, both in vitro and in vivo
after intravenous injection in rats. Finally, we demonstrate
that fSPT is a promising diagnostics tool for detecting and
characterizing blood-borne cell-derived microparticles.
As is illustrated in Figure 1, fSPT sizing is based on
imaging the diffusional motion of fluorescently labeled
particles using a highly sensitive fluorescence microscope
setup (see Materials and Methods in Supporting Informa-
tion). Because of the fluorescent labeling, the particles can
be seen as bright dots on a dark background. Using custom
developed software, the movies are analyzed to obtain the
motion trajectory of each individual particle. By calculating
the diffusion coefficient for each trajectory, a distribution of
empirical diffusion coefficients can be obtained that can be
transformed to a size distribution with the Stokes-Einstein
equation. As discussed in the Theory section of the Support-
ing Information, the precision of the raw size measurement
can be substantially refined by a maximum entropy decon-
volution method (MEM) that eliminates sampling noise and
statistical broadening of the distribution. The power and
usefulness of adding MEM analysis to fSPT is demonstrated
by computer simulations in the Supplementary Results of
the Supporting Information. Futhermore, the fSPT sizing
technique was successfully validated against standard DLS
measurements using dispersions of 100 and 200 nm fluo-
rescent nanospheres (see Supplementary Results in Sup-
porting Information). While similar average sizes and modes
were found using both techniques, the resolution of fSPT
combined with MEM analysis is substantially better as
compared to DLS. Furthermore, contrary to DLS, by fSPT it
was very well possible to measure the size distribution of
nanospheres in full human serum (see Supplementary Re-
sults and Figure S3 in Supporting Information).
Having established that fSPT allows one to measure
accurate size distributions of nanoparticles in biological
fluids, we subsequently investigated whether we can moni-
tor the size of liposomes that have been under investigation
for decades as nanocarriers for drugs in serum, plasma, and
whole blood. Cationic liposomes were made out of equimo-
lar amounts of the cationic lipid 1,2-dioleyl-3-trimethylam-
moniumpropane (DOTAP) and the neutral fusogenic lipid
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). The
DOTAP-DOPE liposomes were fluorescently labeled by in-
corporating 0.1 mol % DOPE-LissamineRhodamineB. Blood
was collected from three healthy donors, a part of which was
used to prepare serum and plasma. The serum, plasma, or
blood was transferred into an artificial blood circulation
system, as illustrated in Supporting Information Figure S5.
FIGURE 1. Schematic overview of fSPT sizing of drug nanoparticles in blood. The nanoparticle formulation is injected in either an artificial
blood circulation system or in a lab animal (rat). Next, small blood samples are collected at regular time intervals and transferred to the fSPT
microscope. After recording movies of the diffusing nanoparticles, their trajectories are calculated using image processing software. Finally,
the diffusion coefficient is estimated for each individual particle, which is then converted to a continuous size distribution using MEM analysis.
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After equilibration of the circulation system to 37 °C, the
DOTAP-DOPE liposomes were injected. Small samples were
collected and measured by fSPT every 30 min over 2 h. The
size distributions are shown in Figure 2 and were obtained
by pooling the data from three donors and applying MEM
analysis. The size distributions are visualized as the relative
frequency Ri with which a size di is present in the particle
population (also see the Theory section in the Supporting
Information). For each size distribution, the sum of all
frequencies equals 1: ∑Ri ) 1. The ordinate axis of the size
distributions is labeled as “f”, which is the more conventional
notation for “frequency”, rather than R. In serum, a slight
tendency toward larger aggregates is noticeable over time
(Figure 2a). In plasma, the aggregation over time is slightly
more pronounced (Figure 2b) but still is far less than what
happens in whole blood (Figure 2c). Compared to serum and
plasma, the aggregation in whole blood is proceeding much
faster and leads to substantially larger aggregates of several
micrometer in diameter. This can also clearly be seen in the
videos provided as Supporting Information (Supplementary
Movies 2 to 4). In plasma, a clear increase in particle
intensity can be seen as compared to serum, which is a
visual confirmation that liposomes are coagulating to form
larger particles. In blood, one can even see micrometer-sized
aggregates (see Supporting Information Supplementary Movie
4a) next to smaller particles (see Supporting Information
Supplementary Movie 4b). These movies are a visual con-
firmation that the increase in size as measured by fSPT in
Figure 2 is effectively due to liposome aggregation and not
for instance merely by binding of the original liposomes to
larger blood components. Taken together, these results
suggest that serum and even plasma are no reliable substi-
tutes for whole blood when it comes to studying the size of
nanoparticles after intravenous injection.
To ensure that the more severe aggregation of the cationic
liposomes in plasma and blood was not induced by (anionic)
heparin, which is used as an anticoagulant, we performed
fSPT sizing experiments on serum samples containing Li-
heparin. This was done by transferring the serum into
similar Li-heparin tubes as were used for collection of the
blood samples. After an incubation period of 15 min, the
heparin containing serum was transferred to the artificial
blood circulation and the liposomes were injected as before.
The results are shown in Figure 2d. While the size distribu-
tions are not identical to the ones in Figure 2a, which is to
be expected since aggregation is a random process, it can
be seen that the presence of heparin does not increases the
rate or extent of aggregation. While further research is
needed, aggregation could come from the adsorption of
soluble proteins, such as fibrinogen, which is present at a
high concentration in plasma and blood but not in serum.
Such proteins may adsorb to the surface of the charged
DOTAP-DOPE liposomes and act as a bridge between them
with the formation of larger aggregates.
Covering the surface of (drug loaded) nanoparticles with
polyethylene-glycol (PEG) chains is currently the most prom-
FIGURE 2. fSPT sizing of nonpegylated DOTAP-DOPE liposomes in serum, plasma, and whole blood. (a) Serum, (b) plasma, (c) whole blood,
and (d) heparin-containing serum was transferred to the artificial blood circulation system. DOTAP-DOPE liposomes were injected and their
size distribution was measured by fSPT at regular time intervals.
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ising method to avoid aggregation in the bloodstream and
subsequent clearance by the reticulo-endothelial system
(RES). Pegylation also allows altering the biodistribution of
the nanoparticles to achieve optimal pharmacokinetics.21,22
Here we have used the fSPT method to examine for the first
time if pegylation indeed suppresses the aggregation of
liposomes in undiluted whole blood. A first type of pegylated
DOTAP-DOPE liposomes was prepared through the addition
(10 mol %) of 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG).
A second type of pegylated liposomes was obtained using
10 mol % N-palmitoyl-sphingosine-1-{succinyl[methoxy-
(polyethylene glycol)2000]} (ceramide-PEG) containing a
C16 acyl chain. It is believed that in contrast to DSPE-PEG
ceramide-PEG lipids can slowly diffuse out of the liposome
wheninjectedinblood,therebyprovidingaformofsheddable
PEG coat. This sheddable coat improves the drug release
properties from endocytosed liposomes when compared to
liposomes containing a conventional, nonsheddable PEG
coat that is obtained by the inclusion of DSPE-PEG.23 After
injection of the liposomes into the artificial blood circulation
system, fSPT size measurements were performed over 2 h
in 30 min time intervals. The experiment was repeated three
times with blood from different donors. The trajectories from
the three blood samples were pooled for each time point
before performing the MEM size analysis. As is evident from
Figure 3a, inclusion of 10 mol % of DSPE-PEG in DOTAP-
DOPE liposomes indeed prevented aggregation in blood
when compared to the nonpegylated liposomes (compare
Figures 3a and 2c). Nevertheless, aggregation still occurs,
although much less, as can be clearly seen from the distribu-
tions at 90 and 120 min. In addition, we tested the effect of
including less DSPE-PEG (5 and 3 mol %), showing that
aggregation becomes progressively worse as the pegylation
degree decreases (see Supporting Information Figure S6).
When compared to DSPE-PEG, ceramide-PEG liposomes
(containing 10 mol % of C16 ceramide-PEG) prove to be
much more prone to aggregation (Figure 3b) although still
less than the nonpegylated ones (Figure 2c). This can be
explained by the ability of the ceramide-PEG molecules to
gradually diffuse out of the liposomes.24 Indeed, the lipid
exchangeability of the ceramide anchor of the ceramide-PEG
conjugate allows its redistribution in other lipid bilayers that
are abundantly present in blood, for example, the plasma
membrane of blood cells. As recently studied by Akinc et
al., small changes in the anchor chain length of PEG-
ceramide analogues can result in significant effects on in vivo
efficacy.25 Let it be noted that the size distributions mea-
sured in whole blood at the first time point in Figure 3a,b
correspond very well to the size distributions of the lipo-
somes measured in buffer, providing further evidence that
fSPT indeed allows to measure correctly the size of lipo-
somes in complex biological fluids.
An ultimate ambition of drug delivery scientists designing
nanoparticles for intravenous administration is to get a clear
view on the size and aggregation of nanoparticles after
intravenous injection in lab animals or patients. As fSPT
sizing in whole blood is feasible and only requires samples
of a few microliters, we took the challenge to analyze by fSPT
liposomes that were first IV injected in rats and then col-
lected from the rats without euthanizing the lab animals. For
each of the three types of liposomes, three rats were injected
with 200 µL of liposome suspension after which small blood
samples (50-100 µL) were taken in Li-heparin vials at
several time points after injection. Nonpegylated liposomes
were found to be severely aggregated already after 5 min
(Figure 4b). After 20 and 40 min, however, we noticed that
the larger particles had disappeared from the blood samples,
resulting in size distributions that were shifted to smaller
sizes. This observation confirms that larger particles are
more rapidly removed from the bloodstream than smaller
ones. After 60 min only, very few liposomes could still be
detected due to which no meaningful size distribution could
be calculated. For the 10 mol % ceramide-PEG liposomes,
we observed some aggregation at 5 min after injection
(Figure 4c). Similar to the nonpegylated liposomes, at later
times after injection no aggregates could be seen anymore
while the number of particles in the fSPT movies was steadily
decreasing. For the 10 mol % DSPE-PEG liposomes (Figure
4d), the number of particles did not decrease so rapidly,
though it is again clear from the distributions that the larger
FIGURE 3. Pegylation of liposomes decreases their tendency to
aggregate in whole blood. (a) fSPT sizing reveals that DOTAP-DOPE
liposomes pegylated with 10 mol % DSPE-PEG remain stable in
whole blood over an extended period of time. (b) Using 10 mol %
ceramide-PEG instead, the liposomes again aggregate over time due
to the ability of ceramide-PEG to diffuse out of the liposomes.
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particles are removed first. From these in vivo experiments,
we conclude that the sizing of nanoparticles in blood should
at first be performed in a closed artificial blood circulation
system since aggregates are quickly removed from the
bloodstream in vivo, which may lead to an underestimation
of the extent of aggregation.
To demonstrate that fSPT sizing is not limited to the study
of exogenous nanoparticles, we have used this technique for
the detection, identification, and sizing of endogenous cell-
derived microparticles (MPs). Cell-derived MPs are particles
in the 0.1 to 1 µm range derived from the plasma membrane
of activated cells or cells entering the apoptotic pathway.26
The characterization of MPs is of importance to the medical
diagnostics field as they could be useful as biomarkers for
metabolic and systemic diseases, as well as for thrombosis
(myocardial infarction, stroke) and cancer.27,28 Apart from
their detection, sizing of MPs is of particular interest as it
provides for an additional confirmation that the detected
particles are indeed cell-derived MPs and not exosomes
(<100 nm) or apoptotic bodies (>1 µm) coming from apop-
totic cells. Furthermore, by using fSPT it is possible to
address the currently open question of whether there is a
relationship between the size of the MPs and their cellular
origin. For example, it has been suggested that platelet-
derived MPs are around 200 nm, whereas endothelial-
derived MPs could be around 400 nm.29 The accurate sizing
of cell-derived MPs is of additional interest to investigate
whether their size is related to the type of stimulus or the
disease background (inflammatory, cancer, etc.).30 As such,
it is clear that the size of MPs is a potential important
pathophysiological parameter. Cell-derived MPs typically
expose phosphatidylserine at the outer leaflet of the mem-
brane that is normally localized in the internal leaflet of
normal quiescent cells. They also display identity antigens
specific for the parent cell, as well as functional glycopro-
teins. By using specific fluorescently labeled antibodies
directed against these glycoproteins or annexin V, which
targets phosphatidylserine, not only size determination in
plasma by fSPT should be possible, but also concomitant
identification of their cellular origin and their functional
characterization. To demonstrate the possibility of detecting
and sizing cell-derived MPs in plasma, MPs were collected
from human microvascular endothelial cells in culture. Next,
Annexin V-FITC or antibodies against CD105 or uPA were
added for labeling of the endothelial MPs. As a negative
control, fluorescently labeled antibodies against CD41 were
added, which is a platelet molecular cluster of differentiation
that is not present in endothelial MPs. Human microparticle-
free undiluted plasma was spiked with endothelial MPs and
examined by fSPT. As shown in the Supplementary Movies
5, 6 and 7 in Supporting Information, endothelial MPs could
be clearly identified with Annexin V-FITC, and TRITC-labeled
antibodies against CD105 and uPA. As expected, the endot-
helial MPs remained invisible in case of Ab CD41 (negative
control) as can be seen in Supporting Information Figure S7.
Sizing of the microparticles was very well possible in plasma
(see Figure 5). The broadest size distribution was obtained
when using Annexin V that targets phosphatidylserine,
which is present on any type of microparticle. The antibody
directed against CD105, a membrane glycoprotein consti-
tutively expressed by endothelial cells, detects also a large
range of microparticles with a mean size of about 315 nm.
However, this marker appeared to be almost absent in small
microparticles of around 100 nm, which are preferentially
enriched in uPA. uPA is the inducible serine protease
expressed by endothelial cells upon stimulation with TNFR
FIGURE 4. DOTAP-DOPE liposomes were intravenously injected in
rats (n) 3) after which small blood samples were collected at regular
time intervals for fSPT size measurements. (a) Nonpegylated lipo-
somes immediately form large aggregates that are quickly removed
from the blood circulation. (b) fSPT measurements on liposomes
with 10 mol % ceramide-PEG indicate a limited amount of ag-
gregates at early time points which are removed at later times. (c)
Liposomes with 10 mol % DSPE-PEG remain stable over the entire
measurement period.
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(tumor necrosis factor R) and seems to be localized in
microparticles of a restricted size as shown in Figure 5. These
data suggest that different types of microparticles derived
from endothelial cells can have a characteristic size range.
To the best of our knowledge, this is the first time that cell-
derived microparticles in the sub-500 nm range have been
identified and characterized in terms of their size in undi-
luted plasma.
In this study we have given ample evidence that fluores-
cence SPT in combination with MEM analysis is the first
technique suited for real-time accurate sizing of nanopar-
ticles in undiluted complex biological fluids, such as plasma
and whole blood. We have shown that MEM analysis sig-
nificantly improves the precision of the raw size distributions
and provides for an improved resolution as compared to DLS
size measurements. An additional advantage of fSPT is that
only very small sample volumes are required, which can be
even less than a microliter. This is beneficial when working
with costly materials, as is often the case in the context of
drug delivery or when only small amounts of a biological
sample are available. Nevertheless, the advantages of fSPT
sizing come with some drawbacks as well. While a single
fSPT size measurement can be performed in a few seconds,
the calculation of the size distribution generally has to be
done off-line due to rather intensive image processing
calculations for obtaining the trajectories. Also, as for any
fluorescence-based technique, care should be taken that the
fluorescent labels do not significantly alter the functionality
and structure of the nanoparticles being studied. We have
verified this explicitly by control experiments using the same
particles but with different fluorescent labels (see Supple-
mentary Results in Supporting Information). Furthermore,
the particle concentration range for fSPT size measurements
is limited due to practical reasons. The upper limit of particle
concentration is dictated by the optical resolution and the
tracking algorithm, resulting in a maximum useful particle
concentration that is typically in the nanomolar range.
Recent advancements in tracking algorithms designed for
high particle densities might prove to be beneficial in this
respect.31,32 Theoretically there is no lower limit to the
particle concentration as the size is calculated for individual
particles. However, it is clear that there should be a sufficient
number of particles in the system to obtain good statistics
within a reasonable time period.
Until now, sizing nanomatter in whole blood was not
possible and diluted serum has been used as a “best”
substitute.33,34 However, using fSPT we have found that the
aggregation of liposomal particles even in undiluted serum
and plasma is an underestimate of what happens in blood.
This leads to the conclusion that serum and plasma, even
when undiluted, can generally not be considered as a reliable
substitute for whole blood when one is interested in the size
and aggregation of intravenously injected nanomatter. When
considering the fSPT sizing data, it seems unlikely that the
observed increase in size of liposomes in blood would be
caused by platelets or cellular microparticles. Platelets are
present in blood at a high concentration of about 200 000/
µL, while they are virtually absent in plasma and serum due
to centrifugation (and clotting in case of serum). Therefore,
if the observed increase in size would be due to adsorption
to platelets, then an increase in size would not have been
observed in serum and plasma. On the other hand, when
considering cell-derived microparticles, it is reported in
literature that they are present in low concentrations in blood
and plasma from healthy individuals (between 1000 and
3000/µL). However, the amount of cellular microparticles is
much higher in serum since they are abundantly released
by platelets during clotting. If the observed increase in size
would be due to sticking of the liposomes to cellular micro-
particles, then aggregation should have been much more
pronounced in serum compared to plasma and blood, which
was not the case. Therefore, from the fSPT data it seems very
unlikely that platelets or cellular microparticles are involved
in the aggregation of cationic liposomes. While further
research is needed, one possible mediator of liposome
aggregation in blood could be fibrinogen, which is more
abundantly available in blood than in plasma and serum.
Furthermore, in relation to recent findings, it would be
interesting to see if the difference between serum and blood
might be related to a different composition of the protein
corona.5 In any case, our results indicate the urgent need
for methods that can analyze particle size in undiluted
biological media.
When comparing nonpegylated DOTAP-DOPE liposomes
with two types of pegylated liposomes, it was found that
liposomes containing DSPE-PEG proved to be the least prone
to aggregation in whole blood, while the ceramide-PEG
functionalized liposomes tended to aggregate more over
time. The latter observation was not unexpected as it is
known that the ceramide-PEG molecules can gradually
diffuse out of the liposomes. Very severe aggregation was
observed for the nonpegylated liposomes. When the same
liposomes were injected intravenously into rats, we found
that the larger particles are removed very rapidly from the
FIGURE 5. Detection and sizing of endothelial-derived microparticles
in plasma by fSPT. The endothelial microparticles could be easily
detected and sized in plasma after staining with Annexin V-FITC or
fluorescently labeled secondary antibodies directed against antibod-
ies to CD105 or uPA (urokinase-type plasminogen activator).
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blood circulation. In agreement with the results from the
artificial blood circulation system, this was most evident for
the nonpegylated liposomes, and to a lesser extent for the
ceramide-PEG and DSPE-PEG DOTAP-DOPE liposomes. The
main conclusion from this is that aggregation experiments
should at first be carried out in a closed in vitro artificial blood
circulation system to assess the extent of aggregation. This can
then be followed by in vivo experiments to relate the aggrega-
tion of the particles to the clearance from the blood circulation.
In future research, we will focus on the development of a
suitable algorithm for the calculation of meaningful number
concentrations from fSPT measurements. This would further
extend the usefulness of the fSPT method to particle clearance
experiments and could provide additional information on
particle number and size when compared to concentration
measurements that rely on the global radioactivity or fluores-
cence signal of a blood sample.35,36
Finally, we have demonstrated that the fSPT sizing
technique can be used for identifying and sizing natural cell-
derived microparticles that were spiked in plasma, provided
that specific fluorescent probes (Annexin V, specific antibod-
ies) are used. In further research, we will explore the
possibility to label specific types of cellular microparticles
directly in pathological plasma. This would be a great benefit
as it avoids the elaborate purification steps normally needed
to isolate cellular MPs. Therefore, fSPT is expected to
contribute to elucidating both the pathophysiological role of
cell-derived MPs and their use as disease biomarkers.
In conclusion, we have demonstrated the first study on
nanoparticle aggregation in undiluted biological fluids, which
was possible by using fSPT combined with MEM analysis.
We expect that fSPT will become an important tool in
pharmacy, biomedical imaging and diagnostics, as well as
other fields where the characterization of nanomatter in
complex fluids is of critical importance.
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